skip to main content

Combination Biologic Therapy — SCE Dermatology MCQ

Instant feedback + full explanation. One question, done properly.

HardDermatopharmacologyCombination Biologic TherapySCE Dermatology

A 40-year-old woman with chronic plaque psoriasis fails three consecutive biologic therapies. Her dermatologist is running out of options. What emerging treatment approach involves combining two biologics?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Combination biologic therapy (e.g., IL-17 inhibitor + IL-23 inhibitor, or IL-17 inhibitor + anti-TNF) is being explored in refractory cases; evidence is limited to case reports/series but may be considered in exceptional circumstances

Combination biologic therapy for refractory psoriasis is an emerging area of interest for patients who have exhausted sequential monotherapy options. Reported combinations include: IL-17 inhibitor + IL-23 inhibitor, anti-TNF + Ustekinumab, and other dual-pathway approaches. Evidence is currently limited to case reports and small series. The rationale is addressing multiple inflammatory pathways simultaneously when single-pathway blockade is insufficient. Safety concerns (infection risk, cost) limit widespread adoption. BAD guidelines do not routinely recommend combination biologics but acknowledge that in exceptional refractory cases, dual biologic therapy may be considered under specialist supervision with enhanced safety monitoring. This remains an area of active clinical research.

Reference: BAD 2020 Biologic Guidelines; BJD Case Reports